Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
St. |
RCV002292249 | SCV002584738 | uncertain significance | Xeroderma pigmentosum, group F | 2022-07-13 | criteria provided, single submitter | clinical testing | The ERCC4 c.1793G>A (p.Arg598Lys) missense change has a maximum subpopulation frequency of 0.0050% in gnomAD v2.1.1 (https://gnomad.broadinstitute.org). The in silico tool REVEL predicts a benign effect on protein function, but to our knowledge this prediction has not been confirmed by functional studies. To our knowledge, this variant has not been reported in individuals with Fanconi anemia or Xeroderma pigmentosum. In summary, the evidence currently available is insufficient to determine the clinical significance of this variant. It has therefore been classified as of uncertain significance. |
Ambry Genetics | RCV003289502 | SCV004008907 | uncertain significance | Inborn genetic diseases | 2023-05-05 | criteria provided, single submitter | clinical testing | The c.1793G>A (p.R598K) alteration is located in exon 8 (coding exon 8) of the ERCC4 gene. This alteration results from a G to A substitution at nucleotide position 1793, causing the arginine (R) at amino acid position 598 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |